Drug firm Natco Pharma on Tuesday said it has received establishment inspection report (EIR) from the US health regulator for its facility near Hyderabad.
In a BSE filing, Natco Pharma announced "successful closure of inspection" with the receipt of an establishment inspection report (EIR) from the US Food and Drug Administration (USFDA) for the inspection conducted at its active pharmaceutical ingredient (API) facility in Mekaguda Village, near Hyderabad, India.
The plant was inspected during the period August 5-9, 2019, it added.
The USFDA gives EIR on closure of inspection of an establishment that is the subject of an FDA or FDA-contracted inspection.
Shares of Natco Pharma were trading 2.63 per cent higher at Rs 596.50 apiece on the BSE.
Disclaimer: No Business Standard Journalist was involved in creation of this content
